Validation of a 5-Year Mortality Prediction Model among U.S. Medicare Beneficiaries.


Journal

Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062

Informations de publication

Date de publication:
12 2020
Historique:
received: 18 05 2020
revised: 21 07 2020
accepted: 11 08 2020
pubmed: 6 9 2020
medline: 19 3 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

A claims-based model predicting 5-year mortality (Lund-Lewis) was developed in a 2008 cohort of North Carolina (NC) Medicare beneficiaries and included indicators of comorbid conditions, frailty, disability, and functional impairment. The objective of this study was to validate the Lund-Lewis model externally within a nationwide sample of Medicare beneficiaries. Retrospective validation study. U.S. Medicare population. From a random sample of Medicare beneficiaries, we created four annual cohorts from 2008 to 2011 of individuals aged 66 and older with an office visit in that year. The annual cohorts ranged from 1.13 to 1.18 million beneficiaries. The outcome was 5-year all-cause mortality. We assessed clinical indicators in the 12 months before the qualifying office visit and estimated predicted 5-year mortality for each beneficiary in the nationwide sample by applying estimates derived in the original NC cohort. Model performance was assessed by quantifying discrimination, calibration, and reclassification metrics compared with a model fit on a comorbidity score. Across the annual cohorts, 5-year mortality ranged from 24.4% to 25.5%. The model had strong discrimination (C-statistics ranged across cohorts from .823 to .826). Reclassification measures showed improvement over a comorbidity score model for beneficiaries who died but reduced performance among beneficiaries who survived. The calibration slope ranged from .83 to .86; the model generally predicted a higher risk than observed. The Lund-Lewis model showed strong and consistent discrimination in a national U.S. Medicare sample, although calibration indicated slight overfitting. Future work should investigate methods for improving model calibration and evaluating performance within specific disease settings.

Sections du résumé

BACKGROUND/OBJECTIVES
A claims-based model predicting 5-year mortality (Lund-Lewis) was developed in a 2008 cohort of North Carolina (NC) Medicare beneficiaries and included indicators of comorbid conditions, frailty, disability, and functional impairment. The objective of this study was to validate the Lund-Lewis model externally within a nationwide sample of Medicare beneficiaries.
DESIGN
Retrospective validation study.
SETTING
U.S. Medicare population.
PARTICIPANTS
From a random sample of Medicare beneficiaries, we created four annual cohorts from 2008 to 2011 of individuals aged 66 and older with an office visit in that year. The annual cohorts ranged from 1.13 to 1.18 million beneficiaries.
MEASUREMENTS
The outcome was 5-year all-cause mortality. We assessed clinical indicators in the 12 months before the qualifying office visit and estimated predicted 5-year mortality for each beneficiary in the nationwide sample by applying estimates derived in the original NC cohort. Model performance was assessed by quantifying discrimination, calibration, and reclassification metrics compared with a model fit on a comorbidity score.
RESULTS
Across the annual cohorts, 5-year mortality ranged from 24.4% to 25.5%. The model had strong discrimination (C-statistics ranged across cohorts from .823 to .826). Reclassification measures showed improvement over a comorbidity score model for beneficiaries who died but reduced performance among beneficiaries who survived. The calibration slope ranged from .83 to .86; the model generally predicted a higher risk than observed.
CONCLUSION
The Lund-Lewis model showed strong and consistent discrimination in a national U.S. Medicare sample, although calibration indicated slight overfitting. Future work should investigate methods for improving model calibration and evaluating performance within specific disease settings.

Identifiants

pubmed: 32889756
doi: 10.1111/jgs.16816
pmc: PMC7781164
mid: NIHMS1645437
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2898-2902

Subventions

Organisme : NIA NIH HHS
ID : R01 AG056479
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA191454
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001111
Pays : United States

Informations de copyright

© 2020 The American Geriatrics Society.

Références

Med Care. 2009 Jun;47(6):626-33
pubmed: 19433995
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
pubmed: 17569110
J Clin Epidemiol. 2011 Jul;64(7):749-59
pubmed: 21208778
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
Pharmacoepidemiol Drug Saf. 2019 May;28(5):584-592
pubmed: 30891850
J Am Coll Cardiol. 2015 Oct 13;66(15):1643-53
pubmed: 26449133
Med Care. 2014 Mar;52 Suppl 3:S75-84
pubmed: 24561763
Epidemiology. 2010 Jan;21(1):128-38
pubmed: 20010215
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90
pubmed: 8410092
Eur Heart J. 2014 Aug 1;35(29):1925-31
pubmed: 24898551
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Pharmacoepidemiol Drug Saf. 2015 Jan;24(1):59-66
pubmed: 25335470
J Geriatr Oncol. 2013 Apr;4(2):157-65
pubmed: 23795223
J Gerontol A Biol Sci Med Sci. 2018 Jun 14;73(7):980-987
pubmed: 29244057
Med Care. 2009 Jun;47(6):610-7
pubmed: 19433991
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328

Auteurs

Rachael K Ross (RK)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Tzy-Mey Kuo (TM)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.

Michael Webster-Clark (M)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Carmen L Lewis (CL)

Division of General Internal Medicine, Department of Internal Medicine, University of Colorado, Aurora, Colorado, USA.

Christine E Kistler (CE)

Division of Geriatric Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Michele Jonsson Funk (M)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Jennifer L Lund (JL)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH